Riskpilot← Back to searchSign inGet full accessFarmako ApS
APSBankruptCVR 40143548Ny Carlsberg Vej 80Wholesale of pharmaceutical and medical goods · NACE 4646Est. 2019— employees
Revenue 2024
DKK -16K
-7% vs 2023
EBITDA margin
100.0%
+7% vs 2023
Equity ratio
-951.6%
Financial strength
Net profit 2024
DKK -16K
+7% vs 2023
| Revenue | DKK -16K | -7% |
| EBITDA | DKK -16K | +7% |
| Net profit | DKK -16K | +7% |
| Total assets | DKK 7K | +0% |
| Equity | DKK -65K | -32% |
| Employees | — | — |
Legal name
Farmako ApS
CVR number
40143548
Legal form
Anpartsselskab
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
7. januar 2019
Share capital
DKK 50.000
Employees
—
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Virksomheden tegnes af en likvidator
Company purpose
Selskabets formål er engrossalg af medicinske præparater og enhver an-den virksomhed eller aktivitet, der direkte eller indirekte kan tjene til dette formåls fremme.
Address
Ny Carlsberg Vej 80
Email
anna.kouparanis@farmako.de
- Event
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Revenue | -29 | -27 | -13 | -13 | -17 | -16 |
| Staff expenses | -0 | -0 | -0 | -0 | -0 | -0 |
| EBITDA | -29 | -27 | -13 | -13 | -17 | -16 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -0 | -0 |
| EBIT | -29 | -27 | -13 | -13 | -17 | -16 |
| Net financials | -0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | -29 | -27 | -13 | -13 | -17 | -16 |
| Tax | -0 | -0 | -0 | -0 | -0 | -0 |
| Net profit | -29 | -27 | -13 | -13 | -17 | -16 |
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Total assets | 34 | 7 | 7 | 7 | 7 | 7 |
| Equity | 21 | -6 | -19 | -33 | -49 | -65 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 13 | 13 | 26 | 39 | 56 | 72 |
| Total debt | 13 | 13 | 26 | 39 | 56 | 72 |
EBITDA margin
-1575000.0%
This company
15.8%
Market median
-9968454% vs market
20192024
Equity ratio
-951.6%
This company
38.2%
Market median
-2591% vs market
20192024
Return on equity
-1574900.0%
This company
18.4%
Market median
-8559339% vs market
20192024
Net profit margin
-1574900.0%
This company
8.1%
Market median
-19443310% vs market
20192024
Asset turnover
-2.30×
This company
1.12×
Market median
-305% vs market
20192024
Debt / equity
1.11×
This company
0.62×
Market median
-79% vs market
20192024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2019-01-07 – 2019-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
AK Management | Management | 2019 | — | — |
KE Management | Management | 2020 | — | — |
AH Unofficial title | Unofficial title | 2025 | — | — |
AK Management | Management | 2019 | — | — |
No data on file.
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 100.0% | 100.0% | 2019 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Farmako ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Anna-Sophia Kouparanis | Management | 0 companies |
| Katrin Eckmans | Management | 0 companies |
| Anders Hoffmann Kønigsfeldt | Unofficial title | 0 companies |
| Andreas Karl Matthias Jägle | Management | 0 companies |